HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…
$10 Million of additional Capital Recently Raised Strengthening Balance SheetKANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:…
PRINCETON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma…
National leader in home health and hospice care to extend AI-enabled speech, language, and cognitive therapy initiative across its network…
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused…
Former Chief Business Leader of Philips’ multi-billion-dollar Precision Diagnosis division and member of Philips’ Executive CommitteeEnd-to-end responsibility for Philip’s CT,…
Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination…
Contributing Funding and a Significant Additional Tool to Combat PTSD and TBIJACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) --…
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the…
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitorOS of…